Loading clinical trials...
Loading clinical trials...
Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)
Conditions
Interventions
ARN-509
Abiraterone acetate
+1 more
Locations
1
United States
Boston, Massachusetts, United States
Start Date
February 5, 2013
Primary Completion Date
May 10, 2014
Completion Date
February 13, 2024
Last Updated
March 4, 2025
NCT06594926
NCT06844383
NCT07177937
NCT06926283
NCT07004582
NCT05919264
Lead Sponsor
Aragon Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions